2025 focused update of the ESC/EAS dyslipidaemia guidelines

Presented at ESC Congress 2025 (Madrid); Mach, Koskinas, Roeters van Lennep and colleagues, European Heart Journal 2025. Revises the LDL-C pathway around earlier combination therapy and keeps lipoprotein(a) as a once-in-a-lifetime measurement and risk modifier, noting that outcomes evidence for specific Lp(a) lowering is still awaited. See the two ESC 2025 videos in Video.